Vanguard Group
DAWN

Vanguard Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Vanguard Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$58.6M Buy
6,282,376
+101,047
+2% +$844K ﹤0.01% 2081
2025
Q3 		$43.6M Buy
6,181,329
+4,834
+0.1% +$33.3K ﹤0.01% 2218
2025
Q2 		$40.1M Buy
6,176,495
+233,252
+4% +$1.6M ﹤0.01% 2234
2025
Q1 		$47.1M Buy
5,943,243
+94,320
+2% +$1.02M ﹤0.01% 2111
2024
Q4 		$74.1M Sell
5,848,923
-38,287
-0.7% -$533K ﹤0.01% 1991
2024
Q3 		$82M Buy
5,887,210
+1,263,938
+27% +$18M ﹤0.01% 1970
2024
Q2 		$63.7M Sell
4,623,272
-151,211
-3% -$2.21M ﹤0.01% 2053
2024
Q1 		$78.9M Buy
4,774,483
+4,737
+0.1% +$70.9K ﹤0.01% 1976
2023
Q4 		$69.6M Buy
4,769,746
+139,992
+3% +$1.7M ﹤0.01% 2043
2023
Q3 		$56.8M Buy
4,629,754
+346,090
+8% +$4.51M ﹤0.01% 2070
2023
Q2 		$51.1M Buy
4,283,664
+1,151,683
+37% +$15M ﹤0.01% 2171
2023
Q1 		$41.9M Buy
3,131,981
+23,008
+0.7% +$449K ﹤0.01% 2254
2022
Q4 		$66.9M Buy
3,108,973
+493,532
+19% +$10.1M ﹤0.01% 2021
2022
Q3 		$52.4M Sell
2,615,441
-11,033
-0.4% -$235K ﹤0.01% 2160
2022
Q2 		$47M Sell
2,626,474
-359,952
-12% -$3.72M ﹤0.01% 2222
2022
Q1 		$29.6M Sell
2,986,426
-48,351
-2% -$639K ﹤0.01% 2569
2021
Q4 		$51.1M Buy
3,034,777
+2,214,704
+270% +$45.5M ﹤0.01% 2335
2021
Q3 		$19.5M Buy
820,073
+200,689
+32% +$4.81M ﹤0.01% 2879
2021
Q2 		$14.1M Buy
+619,384
New +$12.9M ﹤0.01% 3029

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group's DAWN Position: Q4 2025 in Review

Vanguard Group increased its Day One Biopharmaceuticals (DAWN) stake by 1.6% in Q4 2025, buying an estimated $844K and bringing the position to 6,282,376 shares worth $58.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Vanguard Group first reported a position in DAWN in Q2 2021 and has held it in 19 quarters since. The position peaked at $82M in Q3 2024. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Vanguard Group held 6,282,376 shares of Day One Biopharmaceuticals worth $58.6M as of Q4 2025.
  • Vanguard Group bought 101,047 Day One Biopharmaceuticals shares in Q4 2025, an estimated $844K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2081 holding.
  • Vanguard Group first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's Day One Biopharmaceuticals position peaked at $82M in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.